Jacob Plieth - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Jacob Plieth's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Jacob Plieth
Verified
Senior Journalist, ApexOnco
London
Beats
Economic issues in general economic history the Federal Reserve and its policy-making international trade and finance Latin America.
Content
By Jacob Plieth| ApexOnco@ Though Roche’s Tecentriq became the first ever anti-PD-(L)1 drug to be approved in perioperative lung cancer, the company has managed to lose this headstart.
By Jacob Plieth| ApexOnco@ A work-stretched US FDA has several key approval application still to review by the end of 2023. With the fourth quarter of 2023 nearly here, several key first approval verdicts loom for developers of drugs in oncology and related haematology indications. Such catalysts will fall at a time when the FDA is struggling with its workload, a fact that has recently delayed several regulatory decisions.
By Jacob Plieth| ApexOnco@ Though Roche’s Tecentriq became the first ever anti-PD-(L)1 drug to be approved in perioperative lung cancer, the company has managed to lose this headstart.
Company Info
ApexOnco
London, England, United Kingdom
+44 20 7377 0800